Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
-
Alumis to present at Jefferies Global Healthcare Conference on June 4, 2025
-
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
-
Alumis Completes Merger with ACELYRIN
-
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
-
Alumis Stockholders Approve Merger with ACELYRIN
-
Alumis and ACELYRIN Announce Amended Merger Agreement
-
Alumis and ACELYRIN file joint definitive proxy statement for proposed merger, expected to close in 2Q 2025
-
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
-
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements